METCrusaders· @metcrusaders · X·· 3 天前评分45
正文 · 原文
Agree, @dplanchard, and we think access is the piece patients will feel most. A drug that works doesn’t help anyone who can’t get tested or can’t get it prescribed, so MET testing at progression needs to become routine now, before an FDA decision. #lcsm #ESMO26
12 浏览 · 1 赞 · 0 转发 · 0 回复
A major new milestone post-osimertinib! Totally agree with Natasha: a new therapeutic standard, MET testing for all our #EGFRm pts with disease progression post-Osi, and access to Osi + Savolitinib (now the most difficult step for our patients upon our return post-#ESMO26)...在 X 查看被引用的帖子
来源：METCrusaders · x.com